Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience
MetadataShow full item record
Background: Familial hypercholesterolaemia (FH) is a co-dominantly inherited disorder of low-density lipoprotein (LDL) catabolism, causing elevated LDL-cholesterol and premature coronary artery disease (CAD). Several guidelines recommend genetic cascade screening relatives of probands (index cases) with genetically proven FH, but experience in a clinical service setting is limited. Methods: Relatives from 100 index cases with genetically confirmed FH underwent genetic and lipid testing via a centralised screening program in Western Australia. The program's effectiveness was evaluated as the number of newly diagnosed relatives with FH per index case and the proportional reduction in LDL-cholesterol after treatment. Results: Of 366 relatives tested for FH, 188 (51.4%) were found to have a pathogenic mutation. On average, 2 cases were detected per index case. Affected relatives were younger and less likely to have physical stigmata of FH and premature CAD than index cases (p<0.001). Of the new cases, 12.8% had hypertension, 2.7% had diabetes and 16.0% were smokers; 48.4% were already on statin therapy and these were older (p<0.001) and had more vascular risk factors and CAD (p<0.01) than those not on therapy. Significant reductions in LDL-cholesterol (-24.3%, p<0.001) were achieved overall, with previously untreated new cases of FH attaining a maximal average reduction of 42.5% in LDL-cholesterol after drug therapy. Over 90% of subjects were satisfied with screening and care. Conclusion: Genetic cascade screening co-ordinated by a centralised service is an effective and acceptable strategy for detecting FH in an Australian setting. A significant proportion of new cases exhibit other CAD risk factors and are already on statins, but have not received a prior diagnosis of FH. © 2014 Elsevier Ireland Ltd.
Showing items related by title, author, creator and subject.
Pang, J.; Martin, A.; Bates, T.; Hooper, A.; Bell, D.; Burnett, J.; Norman, Richard; Watts, G. (2018)© 2018 Paediatrics and Child Health Division (Royal Australasian College of Physicians). Aim: The aim of this study was to evaluate the clinical outcome of parent-child testing for familial hypercholesterolaemia (FH) ...
Williams, R.; Hooper, A.; Bell, D.; Mamotte, Cyril; Burnett, J. (2015)© 2015 Royal College of Pathologists of Australasia. Phenylketonuria (PKU) is an autosomal recessive disorder of phenylalanine (Phe) catabolism resulting from a deficiency of L-phenylalanine hydroxylase (PAH). An association ...
Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemiaLázaro, P.; Pérez de Isla, L.; Watts, G.; Alonso, R.; Norman, Richard; Muñiz, O.; Fuentes, F.; Mata, N.; López-Miranda, J.; González-Juanatey, J.; Díaz-Díaz, J.; Blasco, A.; Mata, P. (2016)Background: Although familial hypercholesterolemia (FH) confers a high risk of coronary artery disease, most patients are undiagnosed, and little is known about the efficiency of genetic cascade screening programs at ...